A Disposal That Matters
Creo Medical Group Plc (LSE:CREO) published unaudited interim results on 30 September 2026 that combined faster Revenue growth with a clear dependence on a single pending transaction. The company said its Liquidity relies on completing the sale of its remaining 49% interest in Creo Medical S.L., or on alternative short-term financing. Why has that disposal become so important, and what did the half-year figures show?
The Business
Creo Medical is an AIM-quoted medical technology company that develops advanced energy devices used in minimally invasive endoscopic procedures. Its products include the Speedboat device, which the company said has now been used in more than 10,000 procedures, and the MicroBlate range. Creo Medical S.L., referred to by the company as CME, is a Spanish Business in which the group retains a 49% stake following an earlier partial sale. During the period, the group also completed the disposal and outsourcing of its Chepstow Manufacturing operations.
The September Interim Results
On 30 September 2026, Creo reported revenue of £3.2 million for the six months to 30 June 2026, up 45% from £2.2 million a year earlier. Gross Margin improved to 46.9% from 45.5%. The underlying EBITDA loss narrowed to £5.3 million from £7.2 million, and the underlying operating loss fell to £4.9 million from £6.7 million. The loss before tax from continuing operations was £6.4 million. The company said underlying operating costs were 15% lower year on year, helped by the manufacturing changes.
Chief executive Craig Gulliford said the board remained "confident in delivering full year revenue growth in line with existing guidance of 50% to 60%." The company added that revenue growth for the year to date in the third quarter was expected to be approximately 50%.
Cash and Funding
Cash at 30 June 2026 was £7.4 million, compared with £12.4 million at the end of 2025, after a net cash outflow of £5.0 million in the half. That position included proceeds from a share placing of £5.5 million in May 2026 and a £2.0 million convertible Loan note from the Development Bank of Wales.
The interim statement disclosed a material uncertainty over going concern. According to the company, liquidity depends on completing the CME stake disposal or securing alternative short-term financing, which it said is not anticipated to include an share placing. Binding terms for the CME sale are expected in the fourth quarter of 2026. The company presents the sale as a way to simplify the group structure and provide additional liquidity.
Clinical Progress and Risks
Commercially, the company reported that MicroBlate Flex passed 100 clinical cases after the period end, MicroBlate Fine exceeded 50 cases, and Speedboat was used for the first time in a UK private hospital. These milestones support the growth guidance, but revenue remains small relative to the cost base. Key opinion leader presentations at Digestive Disease Week were also cited by the company as clinical validation for its technology.
The principal risk is timing. If binding terms for the CME disposal slip or the transaction fails, the group would need other financing, and its cash fell by £5.0 million in six months despite the placing and loan note. Hospital adoption of new devices can be slow and uneven across markets, and procurement cycles may delay orders. Achieving 50% to 60% revenue growth also depends on continued clinical uptake in the second half.
Conclusion
Creo is counting on its Spanish stake sale because, on its own disclosure, the remaining cash and current losses leave liquidity dependent on that transaction or other short-term funding. The interim results showed faster sales and narrower losses, but delivery of the CME disposal in the fourth quarter is now the most important near-term development for the group.






Please wait processing your request...